Loading
A phase 2 trial of Safusidenib in glioma & glioblastoma, run by Daiichi Sankyo Co., Ltd., active and no longer recruiting.
A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma is a phase 2 interventional study registered as NCT04458272 by Daiichi Sankyo Co., Ltd., with 25 participants enrolled, started 2020-07-08 and due to reach its primary completion in 2023-03-10. Interventions recorded: DS-1001b.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Astrocytoma, IDH-mutant (grades 2 to 4), Glioma & glioblastoma and the tag pipeline.
Shares Daiichi Sankyo and the tag pipeline.
Shares Daiichi Sankyo and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Daiichi Sankyo and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/